BioVie Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
(Exact Name of Registrant as Specified in Its Charter)
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
|
|
||
| (Address of Principal Executive Offices) | (Zip Code) | |
(
(Registrant’s Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| The |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.07. Submission of Matters to a Vote of Security Holders.
On November 7, 2024, BioVie Inc., a Nevada corporation (the “Company”) held its 2024 Annual Meeting of stockholders (the “Annual Meeting”). The following matters were considered:
1. Election of Directors
Stockholders elected all of the Company’s nominees for director for one-year terms expiring at the next annual meeting of stockholders upon election and qualification of their successors. The voting results were as follows:
| For | Withhold | Broker Non-Vote | |||||||
| (1) JIM LANG | 3,013,596 | 186,091 | 1,657,025 | ||||||
| (2) CUONG DO | 3,130,872 | 68,815 | 1,657,025 | ||||||
| (3) MICHAEL SHERMAN | 3,143,406 | 56,281 | 1,657,025 | ||||||
| (4) RICHARD J. BERMAN | 2,999,179 | 200,508 | 1,657,025 | ||||||
| (5) ROBERT HARIRI, M.D. PHD | 3,007,680 | 192,007 | 1,657,025 | ||||||
| (6) SIGMUND ROGICH | 3,138,514 | 61,173 | 1,657,025 |
2. Approval and Ratification of Auditors
Stockholders approved and ratified the appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the 2025 fiscal year. The voting results were as follows:
| For | Against | Abstain | Broker Non-Vote | |||
| 4,526,100 | 62,946 | 267,666 | 1,657,025 |
3. Advisory Say-on-Pay Resolution
Stockholders approved the non-binding advisory proposal on the compensation of the Company’s named executive officers as disclosed in the compensation tables and the related disclosure contained in the proxy statement. The voting results were as follows:
| For | Against | Abstain | Broker Non-Vote | |||
| 3,004,131 | 108,126 | 87,430 | 1,657,025 |
4. Amendment and Restatement of 2019 Omnibus Equity Incentive Plan
Stockholders approved the amendment and restatement of the 2019 Omnibus Equity Incentive Plan to increase the number of shares authorized for issuance up to 1,250,000.
| For | Against | Abstain | Broker Non-Vote | |||
| 2,963,641 | 181,639 | 54,407 | 1,657,025 |
| -1- |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: November 8, 2024
| BIOVIE INC. | |||
| By: | /s/ Joanne Wendy Kim | ||
| Name: | Joanne Wendy Kim | ||
| Title: | Chief Financial Officer | ||
| -2- |